Project Grant R01HL186410
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...
- The National Heart, Lung, and Blood Institute awarded Worcester Polytechnic Institute $532,935 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the endothelial glycocalyx in sepsis-induced coagulopathy. The research targets sepsis-associated coagulopathy, a condition characterized by uncontrolled thrombosis, large vessel occlusion, and stroke that resists traditional anticoagulation therapies. The project will examine how sepsis...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $670,622 as a Project Grant (R01HL180941) on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the role of endogenous RNA sensing in the amplification of lung injury. The research focuses on how lung infections induce widespread lung vascular endothelial injury through a cycle of endothelial barrier breakdown and inflammatory cell influx. The project...
- The National Heart, Lung, and Blood Institute awarded Yale University $577,016 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to support research into the molecular mechanisms underlying endothelial von Willebrand factor exocytosis. The research addresses how von Willebrand factor (VWF), a multifunctional plasma glycoprotein essential to hemostasis and thrombosis, is mobilized from vascular stores in endothelial cells. VWF is synthesized and stored in...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $835,583 under Project Grant R01HL188033 on September 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into von Willebrand factor as a driver of trauma-induced thromboinflammation. The project investigates how traumatic injury triggers pathological modifications of von Willebrand factor that propagate neutrophil interactions, netosis, and microvascular...
- The National Heart Lung and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded $743,131 to the University of Wisconsin - Madison on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory mechanisms of the vessel wall in deep vein thrombosis. The research addresses thrombospondin-1 (TSP1), a matricellular protein upregulated in endothelial cells during DVT. The project tests...
- The National Heart, Lung, and Blood Institute awarded Emory University $198,728 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of claudin11 in regulating endothelial barrier function in sepsis. The research examines how the tight junction protein claudin11 forms a signaling hub with pannexin1 to regulate vascular barrier function in response to inflammatory cytokines associated with sepsis. Sepsis affects approximately 1.7...
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $346,960 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 20, 2025, to investigate the inflammatory-fibrotic axis in advanced pulmonary sarcoidosis-related fibrosis (APSF). The research applies single-cell RNA sequencing (scRNA-seq) and surface protein indexing to identify key regulators and signaling pathways within CD14+ monocyte subpopulations in individuals with chronic...
- The National Heart, Lung, and Blood Institute awarded Versiti Blood Health, Inc. $1,069,072 on March 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode kindlin-3 signaling in platelets and neutrophils. The research investigates the regulatory role of kindlin-3, a critical signaling adaptor in hematopoietic cells, in thrombosis and inflammation. The project focuses on elucidating molecular mechanisms by which kindlin-3 regulates platelet activation during...